HTA & Market Access

All Items

• Innovation in the management of the breast cancer patient pathway: from correct identification to target therapies. Perspectives, opportunities and insights

  Vincenzo Adamo, Mario Airoldi, Gianni Amunni

  42-47

  DOI: https://doi.org/10.33393/ao.2024.3084

• Using the Nephrology Referral Form in Italian primary care to improve the care pathway of patients with anemia or other complications related to chronic kidney disease: survey findings

  Giuseppe Pompilio, Francesca Pia Chiara Leone, Marco Gullì, Davide Integlia

  37-41

  DOI: https://doi.org/10.33393/ao.2024.3066

• Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy

  Patrizio Armeni, Elena Compagnucci , Gionata Fiorino, Vincenzo Lolli, Grazia Mazzone , Ambrogio Orlando, Mariabeatrice Principi, Roberto Ravasio, Fernando Rizzello, Edoardo Vincenzo Savarino, Francesca Tombari

  21-29

  DOI: https://doi.org/10.33393/ao.2024.2893

• Early access according to Law 648: a review for the clinician

  Valentina Drago, Federica Giuffrida

  124-127

  DOI: https://doi.org/10.33393/ao.2023.2946

• Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy

  Chiara Vassallo, Beatrice Canali, Francesca Fiorentino, Paolo Morelli, Silvia Ripoli, Laura Fioravanti

  103-109

  DOI: https://doi.org/10.33393/ao.2023.2609

• Refractory CMV infection in post-transplant phase: epidemiological framing in the Italian context, current patient management and unmet needs

  Marianna Morani, Fausto Baldanti, Fabio Ciceri, Franco Citterio, Mariano Ferraresso, Corrado Girmenia, Umberto Maggiore, Massimo Martino, Francesco Onida, Luciano Potena, Fabio Vistoli, Paolo Antonio Grossi

  97-102

  DOI: https://doi.org/10.33393/ao.2023.2564

• Erratum in “Percorso diagnostico-terapeutico e modello organizzativo per l’erogazione della terapia genica nelle distrofie retiniche ereditarie in real-life”

  87

  DOI: https://doi.org/10.33393/ao.2023.2616

• Comments to “Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy”

  Ottavio Secchi, Andrea Franchi, Armando Lunello

  82-86

  DOI: https://doi.org/10.33393/ao.2023.2600

• Cost-minimization analysis of HYQVIA® in the treatment of primary immunodeficiency disease (PID) and secondary immunodeficiency disease (SID) in Italy

  Roberto Ravasio, Silvia Ripoli

  69-77

  DOI: https://doi.org/10.33393/ao.2023.2584

• Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy

  Roberto Ravasio, Raffaella Viti, Antonio Saverio Roscini

  13-21

  DOI: https://doi.org/10.33393/ao.2023.2515

• Model for estimating the impact of healthcare costs in non-hospitalized Covid-19 patients treated with remdesivir

  Matteo Ruggeri, Alessandro Signorini, Silvia Caravaggio, Marco Falcone, Giovanni Di Perri

  114-121

  DOI: https://doi.org/10.33393/ao.2022.2473

• Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test

  Rossella Bitonti, Federica Demma, Massimiliano Rea, Gianluca Furneri

  105-111

  DOI: https://doi.org/10.33393/ao.2022.2447

• Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor

  Roberto Ravasio, Holly Cranmer, Izzie Kearns , Raffaella Viti, Simone Corinti

  92-104

  DOI: https://doi.org/10.33393/ao.2022.2450

• Emicizumab in hemophilia A with inhibitors: clinical and economic impact of its use in a Cuban patient

  Dunia Castillo-Gonzàles, Irianys Álvarez Sardiñas, Consuelo Macías Abraham, Alex G. Muñoz Bedoya

  83-86

  DOI: https://doi.org/10.33393/ao.2022.2438

• Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy

  Federica Demma, Pierpaola Arpa

  36-42

  DOI: https://doi.org/10.33393/ao.2022.2405

• Economic impact of Enterosgel® in the hospital treatment of diarrhoeal syndromes associated with different disease conditions

  Roberto Ravasio, Paola Raimondo

  99-105

  DOI: https://doi.org/10.33393/ao.2021.2345

• Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy

  Gian Luca Breschi, Federica Demma, Paolo Morelli, Maria De Francesco

  81-87

  DOI: https://doi.org/10.33393/ao.2021.2263

• Orthopaedic device manufacturers’ perspective on MDR compliance

  Peter Fennema, Hassan Achakri

  34

  DOI: https://doi.org/10.33393/ao.2021.2280

• Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy Analisi di costo-efficacia dei farmaci ad azione antivirale diretta nel trattamento dell’epatite cronica C nella popolazione carceraria italiana

  Roberto Ravasio, Luciano Lucania, Roberto Ranieri, Raquel Dominguez

  103-111

  DOI: https://doi.org/10.33393/ao.2020.2190

• Time to reimbursement and negotiation condition in Italy for drugs approved by the European Medicines Agency during the period 2014-2019

  Mariangela Prada, Letizia Rossi, Matteo Mantovani

  89-94

  DOI: https://doi.org/10.33393/abtpn.2020.2184

• Model for estimating the healthcare costs and capacity of intensive care units in Italy in the treatment of patients with COVID-19: remdesivir impact assessment

  Matteo Ruggeri, Alessandro Signorini, Carlo Drago, Francesco Rosiello, Marco Marchetti

  95-102

  DOI: https://doi.org/10.33393/abtpn.2020.2213

• Socioeconomic impact of migraine in Italy: Results of a national survey

  Mihaela Nica, Delia Colombo, Roberto Ravasio, Carla Rognoni

  80-88

  DOI: https://doi.org/10.33393/abtpn.2020.2189

• Economic evaluation of low-dose SKA cytokines in patients with rheumatoid arthritis in maintaining low disease activity or remission

  Roberto Ravasio, Alberto Migliore

  67-73

  DOI: https://doi.org/10.33393/abtpn.2020.2153

• A Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy Analisi di budget impact del biosimilare di pegfilgrastim nel trattamento della neutropenia febbrile in Italia

  Roberto Ravasio, Lorenzo Antonuzzo, Marco Danova, Paolo Pronzato

  4-8

  DOI: https://doi.org/10.33393/abtpn.2020.2030

• The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)

  Claudio Jommi, Roberto Ravasio

  78-85

  DOI: https://doi.org/10.33393/abtpn.2019.302